General Mills, Inc.

▲ Bull Case

• ◆Blue Buffalo is a premium pet food platform compounding at 6-10%/yr — the most valuable asset in the portfolio. Pet humanization is one of the most durable secular trends in consumer goods. Blue Buffalo holds 20% US natural dog food market share, is expanding rapidly into cat food (+15%/yr) and treats, and will reach $4B+ revenue by FY2030. As pet grows to 18-20% of GIS revenue, the blended portfolio multiple expands organically toward higher-growth, higher-multiple assets.
• ◆The cereal moat is more durable than the market implies. Cheerios has 34% US adult cereal market share and 84% of K-12 foodservice penetration. These brands have 80+ year heritage. GLP-1 drugs reduce appetite but do not eliminate breakfast need. Historical precedent shows every 'cereal killer' thesis (low-carb, keto, protein bars) has resulted in moderation — not collapse — of cereal consumption. The brand equity of Cheerios, Nature Valley, and Pillsbury provides a durable floor private label cannot easily replicate in premium/trusted segments.
• ◆At 9x trough EPS, the stock offers a free call option on any recovery. GIS is investment-grade, generates $2B+ annual FCF, and owns globally recognized brands. The 9x multiple implies a further 30-40% earnings decline from trough — a 5% probability outcome, not the 50% base case. If earnings merely stabilize at $4.00-4.10/share, the stock at 13x = $52-53, a 58% return from $33, with 7.4% dividend income while waiting. The upside/downside ratio (excluding the severe case) is 19:1.

▼ Bear Case

• ◆GLP-1 drugs could permanently impair the processed food demand curve. GLP-1 adoption is accelerating from ~1M US users in 2022 to 5M+ in 2026 and potentially 20M+ by 2028 as oral GLP-1s become available. Clinical studies show users consume 15-25% fewer calories and specifically reduce processed carbohydrate intake. If penetration reaches 8-10% of US adults by 2030, General Mills' core cereal, snacks, and baking categories could face structural volume declines of 3-5%/yr — permanent, not cyclical. At -4%/yr volume, EPS falls to $3.00-3.20 and the current 9x P/E is not a discount but fair value.
• ◆$14.5B net debt creates a leverage trap that constrains strategic options. GIS's leverage (3.5-4x EBITDA) limits buybacks when the stock is cheapest, constrains M&A optionality, creates earnings sensitivity to interest rate changes on refinancing, and forces capital allocation toward debt service rather than brand investment. Competitors like Nestlé or Mars with pristine balance sheets can outspend GIS on innovation, marketing, and distribution precisely when GIS is in austerity — making the value trap scenario self-reinforcing.
• ◆North America Retail volume declines may be structural, not cyclical. Two consecutive years of volume declines (-1% to -3%/yr) following years of price increases suggests the market has structurally repriced. Private label has permanently captured 2-4% market share in cereals and snacks. Walmart's Great Value brand expansion directly targets GIS's mass-channel revenue. If the management turnaround fails to arrest volume decline, the revenue trajectory is $19.5B → $18.5B → $17.5B, EBITDA compression follows mechanically, and the leverage trap accelerates.

“Is General Mills a fallen compounder — a cyclical oversell of a defensible franchise at a once-in-a-decade valuation — or a value trap where GLP-1 drugs plus private label competition are creating permanent structural impairment that justifies 9x P/E as fair value rather than a discount? The bull argues Blue Buffalo is growing, the cereal franchise has 80-year brand equity, the yogurt divestiture simplifies the portfolio, and 9x P/E prices in Armageddon that isn't coming. The bear argues GLP-1 drugs represent a structural break in processed food demand, $14.5B debt prevents management from fighting back, and private label has permanently captured share in cereal. Resolution signals: Q1 FY2027 volume data (summer 2026); GLP-1 penetration rate trajectory; Blue Buffalo market share vs. Mars/Nestlé Purina.”

• ◆Q1 FY2027 earnings (Sep–Oct 2026): first post-yogurt volume data point — flat or positive core volume would confirm the cyclical (not structural) thesis and trigger re-rating
• ◆Q2 FY2027 earnings (Jan 2027): second consecutive quarter of volume data establishing a pattern; two positive quarters would significantly compress the bear case probability
• ◆Blue Buffalo organic growth sustaining ≥7%/yr: confirms the most valuable portfolio asset is on track toward $3.0B+ revenue by FY2027, supporting a higher blended multiple
• ◆Net debt reduction trajectory: each quarter of confirmed de-lever toward the <3.0x target expands buyback optionality and reduces financial risk premium
• ◆GLP-1 penetration plateau: if US GLP-1 user growth decelerates or compliance/retention proves low, the single largest overhang on the stock lifts
• ◆Blue Buffalo strategic separation or M&A interest: any signal that the pet business could be valued independently (IPO, partial sale, strategic interest) would surface $8–12B of embedded value currently obscured by the conglomerate discount

• ◆GLP-1 structural demand impairment (25–30% probability, HIGH severity): processed carbohydrate categories face permanent volume decline of 3–5%/yr if oral GLP-1 penetration reaches 8–10% of US adults by 2030
• ◆Private label continued market share gains (30–35% probability, MEDIUM severity): US private label cereal share rising from ~20% toward 30% would collapse GIS pricing power and accelerate revenue erosion
• ◆Leverage trap — $14.5B net debt constraining buybacks and strategic options (structural, ongoing): 3.5–4x EBITDA handcuffs capital allocation when flexibility is most needed
• ◆Dividend cut (8–12% probability, HIGH severity): would trigger income investor exit and signal FCF deterioration below $1.5B or management loss of confidence in earnings trajectory
• ◆Blue Buffalo competitive deceleration (20–25% probability, MEDIUM-HIGH severity): growth slowing below 4%/yr would impair the highest-multiple, highest-growth asset in the portfolio
• ◆Food recall or safety event (5–10% probability, SEVERE): no early warning signal; brand damage and liability could be outsized given scale
• ◆Debt-financed M&A (5–10% probability, MEDIUM-HIGH severity): any additional leveraged acquisition would further entrench the leverage trap and delay the de-lever thesis